GLPG3970   Click here for help

GtoPdb Ligand ID: 12157

Synonyms: compound 88 [WO2019238424A1] | GLPG-3970
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GLPG3970's chemical structure was revealed during the first disclosures session at the 2022 ACS meeting in Chicago. This is Galapagos' oral, salt inducible kinase 2 and 3 (SIK2/3) inhibitor that was proposed for treating inflammatory diseases.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 68.54
Molecular weight 504.2
XLogP 3.74
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(cc2c1C(=O)N(CC2)CC(F)(F)F)c1cnc2n1ccc(c2)OCCN1CCOCC1
Isomeric SMILES COc1cc(cc2c1C(=O)N(CC2)CC(F)(F)F)c1cnc2n1ccc(c2)OCCN1CCOCC1
InChI InChI=1S/C25H27F3N4O4/c1-34-21-13-18(12-17-2-4-31(16-25(26,27)28)24(33)23(17)21)20-15-29-22-14-19(3-5-32(20)22)36-11-8-30-6-9-35-10-7-30/h3,5,12-15H,2,4,6-11,16H2,1H3
InChI Key XASOHFCUIQARJT-UHFFFAOYSA-N
Immunopharmacology Comments
The salt-inducible kinases (SIKs) regulate physiological processes including innate immunity (macrophage and mast cell function), circadian rhythms, osteogenesis, skin pigmentation and metabolism. SIK inhibitors are being investigated for therapeutic potential in a number of human diseases. In the inflammation setting SIK inhibitors are predicted to suppress aberrant inflammatory activity in myeloid cell driven diseases (e.g. rheumatoid arthritis, psoriatic arthritis and psoriasis, inflammatory bowel diseases) and in mast cell driven diseases such as asthma.